In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer licenses Guilford's NAALADase inhibitors; ends deal

Executive Summary

Pfizer licensed exclusive worldwide development and marketing rights from Guilford Pharmaceuticals (sells pharmaceuticals to hospital and neurology markets) to a class of compounds--NAALADase inhibitors--which have shown potential in Phase I trials as peripheral and central neurodegenerative disease therapeutics. The company is paying Guilford $15mm plus additional considerations for the rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies